FTC v. Amare Global Holdings Inc.

Amare Global Holdings Inc. allegedly misrepresented to parents and other consumers that its dietary supplements marketed for children and adults could treat or cure health conditions such as depression, anxiety, and ADHD. The company also allegedly misled its seller recruits about their potential earnings as “brand partners.” Amare Global Holdings Inc., Shawn Talbott, Patrick Hintze, and David Chung are accused of making false, misleading, and unsubstantiated claims. The FTC alleges Amare's claims violated the FTC Act by claiming without substantiation that Amare’s products would lower, reduce, or regulate cortisol; raise, increase, or normalize serotonin, dopamine and GABA; and cure, treat, or mitigate depression, anxiety and ADHD. The FTC also alleges Amare made deceptive earnings claims about the money brand partners can make from selling the company’s products.

Summary generated from official Federal Trade Commission press release